Hutchison China MediTech Ltd ("Chi-Med"): Chi-Med's pipeline has eight novel late stage oncology candidates with six Phase 3 trials and 20+ Phase 1b/2 trials currently underway that are fueled by its profitable Chinese commercial platform. Fruquintinib (VEGFR inhibitor, LLY-partnered) for colorectal cancer was approved in China in September 2018 and Phase 3 topline results in NSCLC is expected in late 2018. Savolitinib (C-Met inhibitor, AZN-partnered) for papillary renal cell carcinoma initiated a global Phase 3 trial in June 2017. AZN has the decision on strategy for Phase 3 registration and potential Breakthrough Therapy in NSCLC in combination with Tagrisso. Epitinib (1st-gen EGFR TKI) expects to initiate China Phase III study in 1L EGFRm NSCLC w/ brain mets in H2 2018. HMPL-523 (Syk inhibitor) preliminary safety and efficacy data from Phase I dose escalation studies in hematological cancer is expected in H2 2018.
21st Floor, Hutchison House
10 Harcourt Road
Hong Kong

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2017 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.